Article Text

Download PDFPDF
Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes
  1. Rocio Lago1,
  2. Rodolfo Gomez1,
  3. Carlos Dieguez2,
  4. Juan J Gomez-Reino1,
  5. Francisca Lago3,
  6. Oreste Gualillo1
  1. 1
    Santiago University Clinical Hospital, Research Laboratory 4 (NEIRID LAB, Laboratory of Neuro Endocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago de Compostela, Spain
  2. 2
    University of Santiago de Compostela, Department of Physiology, School of Medicine, Santiago de Compostela, Spain
  3. 3
    Santiago University Clinical Hospital, Research Laboratory 1 (Molecular and Cellular Cardiology), Santiago de Compostela, Spain
  1. Oreste Gualillo, Santiago University Clinical Hospital, Area, NEIRID Laboratory 4, Trav. Choupana sn, 15706 Santiago de Compostela, Spain; gualillo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Obestatin is a 23 amino acid amidated peptide identified as the product of posttranslational cleavage of the preproghrelin,1 the polypeptide precursor of ghrelin. Obestatin has been reported to have actions opposite to ghrelin,2 but its ghrelin antagonist properties are still unclear and controversial. As our group has identified ghrelin as a peptide synthesised and secreted by chondrocytes, with significant biological activity on cartilage cell metabolism,3 it was conceivable that obestatin might exert some physiological action on chondrocytes. These cells are emerging as a local producer and target of several endocrine factors including ghrelin3 and leptin.4 5 It is of note that the obestatin co-joined hormone ghrelin has been revealed as a convergent factor between bone metabolism and energy homeostases.6 7 So, it was plausible to verify the …

View Full Text


  • The research described in this article has been supported by the Spanish Ministry of Health, Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (FIS PI 05/0525, PI030115, PI050419) and Xunta de Galicia. O.G. and F.L. are recipients of a contract under the “Programme of stabilization of researchers” co-funded by the Instituto de Salud Carlos III and SERGAS. R.L. and R.G. are recipients of a project-associated fellowship from Instituto de Salud Carlos III.